Scynexis Inc Cash Flow Conversion Efficiency
Scynexis Inc cash flow conversion efficiency. Based on the latest financial reports, Scynexis Inc (SCYX) has a cash flow conversion efficiency ratio of -0.222x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.88 Million) by net assets ($66.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Scynexis Inc (2012–2025)
Cash flow conversion efficiency of Scynexis Inc from 2012 to 2025. This chart illustrates how Scynexis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Scynexis Inc (SCYX) stock price for real-time trading data and today's change.
Scynexis Inc Cash Flow Conversion Ratio Explained
Scynexis Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Scynexis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scynexis Inc ranked by their cash flow conversion efficiency. Also see SCYX market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Widodo Makmur Perkasa PT
JK:WMPP
|
-0.003x |
|
Meditera Tibbi Malzeme Sanayi ve Ticaret AS
IS:MEDTR
|
0.057x |
|
Domiki Kritis S.A.
AT:DOMIK
|
0.028x |
|
Innometry Co. Ltd
KQ:302430
|
0.019x |
|
Bangkok Dec-Con Public Company Limited
BK:BKD
|
-0.006x |
|
Hammer Metals Ltd
AU:HMX
|
-0.028x |
|
Omesti Bhd
KLSE:9008
|
0.045x |
|
Elliptic Laboratories AS
OL:ELABS
|
-0.080x |
Annual Cash Flow Conversion Efficiency for Scynexis Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Scynexis Inc from 2012 to 2025. Review free cash flow generation of Scynexis Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $49.38 Million | $-5.28 Million | -0.107x | +75.46% |
| 2024-12-31 | $55.08 Million | $-24.01 Million | -0.436x | -152.87% |
| 2023-12-31 | $72.96 Million | $60.16 Million | 0.825x | +103.34% |
| 2022-12-31 | $3.23 Million | $-79.88 Million | -24.709x | -1768.45% |
| 2021-12-31 | $41.26 Million | $-54.56 Million | -1.322x | +39.02% |
| 2020-12-31 | $22.76 Million | $-49.35 Million | -2.169x | +26.64% |
| 2019-12-31 | $12.89 Million | $-38.12 Million | -2.956x | -225.90% |
| 2018-12-31 | $31.23 Million | $-28.32 Million | -0.907x | +20.91% |
| 2017-12-31 | $21.41 Million | $-24.56 Million | -1.147x | -36.05% |
| 2016-12-31 | $34.82 Million | $-29.35 Million | -0.843x | -44.08% |
| 2015-12-31 | $41.95 Million | $-24.55 Million | -0.585x | -106.51% |
| 2014-12-31 | $33.43 Million | $-9.47 Million | -0.283x | -157.23% |
| 2013-12-31 | $-8.70 Million | $-4.31 Million | 0.495x | -9.69% |
| 2012-12-31 | $-19.33 Million | $-10.60 Million | 0.548x | -- |
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the tre… Read more